Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

PAVM PAVmed Inc

0,742

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 13:00:05

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

PAVmed (NASDAQ:PAVM)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more PAVmed Charts.

PAVmed (NASDAQ:PAVM)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more PAVmed Charts.

News PAVmed Inc

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Donnerstag 13 Juni 2024 (2 Wochen vor) • PR Newswire (US)

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
Mittwoch 12 Juni 2024 (2 Wochen vor) • PR Newswire (US)

PAVmed Provides Business Update and First Quarter 2024 Financial Results
Dienstag 14 Mai 2024 (1 Monat vor) • PR Newswire (US)

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
Montag 13 Mai 2024 (1 Monat vor) • PR Newswire (US)

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
Donnerstag 9 Mai 2024 (2 Monate vor) • PR Newswire (US)

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
Dienstag 7 Mai 2024 (2 Monate vor) • PR Newswire (US)

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
Freitag 3 Mai 2024 (2 Monate vor) • PR Newswire (US)

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Donnerstag 2 Mai 2024 (2 Monate vor) • PR Newswire (US)

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
Donnerstag 2 Mai 2024 (2 Monate vor) • PR Newswire (US)

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Dienstag 30 April 2024 (2 Monate vor) • PR Newswire (US)

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
Montag 29 April 2024 (2 Monate vor) • PR Newswire (US)

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Montag 8 April 2024 (3 Monate vor) • PR Newswire (US)

Weitere PAVmed Inc News-Artikel

Financial Select Sector

Deutsche Telekom

Energy Select Sector SPDR

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen